18th Nov 2015 12:23
18 November 2015
Allergy Therapeutics plc
("Allergy Therapeutics" or the 'Company")
Result of Annual General Meeting
Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that at the Annual General Meeting held today, all the resolutions put to that meeting were duly passed.
For further information:
Allergy Therapeutics | +44 (0) 1903 845 820 |
Manuel Llobet, Chief Executive Officer | |
Ian Postlethwaite, Finance Director | |
Panmure Gordon | +44 (0) 20 7886 2500 |
Freddy Crossley / Peter Steel / Duncan Monteith, Corporate Finance | |
Tom Salvesen, Corporate Broking | |
FTI Consulting | +44 (0) 20 3727 1000 |
Simon Conway / Mo Noonan / Victoria Foster Mitchell |
Note to editors:
About Allergy Therapeutics
Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the last financial year of £43 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.
Related Shares:
Allergy Thera.